Seagen, A Wholly Owned Subsidiary Of Pfizer

This early-phase study tests a new drug called SEA-CD70, alone or with standard drugs azacitidine and venetoclax, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goal is to check safety and find the right dose. About 178 participants will b…

This study tests a combination of two drugs, disitamab vedotin and tucatinib, for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo can shrink or control tumors and what side effects occur. About 172 adults with these …

This phase 2 trial is testing whether the drug disitamab vedotin, alone or with pembrolizumab, can shrink tumors in people with advanced bladder cancer that has spread or cannot be removed. The study includes 372 participants whose cancer cells have a protein called HER2. Researc…

This early-stage trial tests a new drug, sigvotatug vedotin, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find the safest dose and check for side effects, both when the drug is used alone and with other cancer treatments. Ab…

This early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This study tests whether adding tucatinib and trastuzumab to standard chemotherapy helps people with HER2-positive colorectal cancer that has spread or can't be removed. About 400 participants will be randomly assigned to the new combo or standard treatment. The goal is to see if…